HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

TUEBINGEN, Germany, March 14, 2024 (GLOBE NEWSWIRE) — HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, today published clinical and preclinical results on its first-in-class MKK4 inhibitor HRX-215 in the prestigious journal Cell. The manuscript, available online here (DOI: 10.1016/j.cell.2024.02.023), describes strongly enhanced liver regeneration and prevention of liver failure by HRX-215 in preclinical model systems and a first-in-human trial showing safety and tolerability. HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

LabNews Media LLC

labnews.ai 的主编是 Marita Vollborn 和 Vlad Georgescu。自 1994 年以来，他们一直是畅销书作家、科学作家和科学记者。更多关于他们的写作信息，请访问 X-Press Journalistenbüro (https://xpress-journalisten.com)。更多维基百科信息：关于 Marita：https://de.wikipedia.org/wiki/Marita_Vollborn 关于 Vlad：https://de.wikipedia.org/wiki/Vlad_Georgescu

查看完整简介